PUOTI, Massimo
 Distribuzione geografica
Continente #
NA - Nord America 7.193
AS - Asia 3.212
EU - Europa 2.414
SA - Sud America 495
AF - Africa 66
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 13
Totale 13.413
Nazione #
US - Stati Uniti d'America 7.105
CN - Cina 1.205
SG - Singapore 1.062
UA - Ucraina 748
DE - Germania 422
BR - Brasile 421
HK - Hong Kong 356
FI - Finlandia 229
IT - Italia 198
GB - Regno Unito 160
FR - Francia 158
IN - India 140
VN - Vietnam 139
TR - Turchia 129
RU - Federazione Russa 118
IE - Irlanda 117
PL - Polonia 113
CA - Canada 51
BD - Bangladesh 44
SE - Svezia 41
AR - Argentina 26
ZA - Sudafrica 25
IQ - Iraq 22
MX - Messico 22
JP - Giappone 19
AU - Australia 16
BE - Belgio 16
NL - Olanda 16
PK - Pakistan 15
EU - Europa 13
VE - Venezuela 13
LT - Lituania 12
SA - Arabia Saudita 12
EC - Ecuador 11
AT - Austria 10
CO - Colombia 10
ES - Italia 10
UZ - Uzbekistan 10
CH - Svizzera 9
IR - Iran 9
NG - Nigeria 8
CL - Cile 7
KE - Kenya 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
MA - Marocco 5
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
HU - Ungheria 4
ID - Indonesia 4
JM - Giamaica 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RS - Serbia 4
TN - Tunisia 4
CZ - Repubblica Ceca 3
EG - Egitto 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
AL - Albania 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
KG - Kirghizistan 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
EE - Estonia 1
ET - Etiopia 1
GY - Guiana 1
HN - Honduras 1
LK - Sri Lanka 1
LR - Liberia 1
LY - Libia 1
MK - Macedonia 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
TH - Thailandia 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
Totale 13.411
Città #
Woodbridge 766
Ashburn 701
Fairfield 665
Jacksonville 553
Singapore 543
Houston 487
San Jose 409
Hong Kong 356
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 304
The Dalles 229
Nanjing 228
Princeton 193
Chandler 177
Beijing 172
Los Angeles 120
Dublin 116
Helsinki 113
Warsaw 112
New York 107
Istanbul 102
Lauterbourg 98
Nanchang 90
Dearborn 80
Moscow 70
Shenyang 59
Des Moines 55
Ho Chi Minh City 50
Changsha 49
Buffalo 48
Munich 47
San Diego 46
Shanghai 46
Jinan 43
Tianjin 43
Hebei 41
São Paulo 40
Jiaxing 36
Lancaster 33
Milan 33
San Francisco 33
London 32
Redondo Beach 32
Brescia 31
Washington 29
Orem 23
Chennai 22
Verona 21
Dallas 20
Hanoi 20
Kunming 20
Santa Clara 19
Tokyo 19
Toronto 19
Brooklyn 18
Chicago 17
Hangzhou 17
Brussels 16
Charlotte 16
Lanzhou 16
Taizhou 16
Council Bluffs 15
Kocaeli 15
Rio de Janeiro 15
Zhengzhou 15
Guangzhou 14
Brasília 13
Johannesburg 13
Leawood 13
San Mateo 13
Stockholm 12
Denver 11
Haikou 11
Monmouth Junction 11
Norwalk 11
Atlanta 10
Boston 10
Phoenix 10
Augusta 9
Belo Horizonte 9
Campinas 9
Curitiba 9
Delhi 9
Manchester 9
Montreal 9
Ningbo 9
Nuremberg 9
Porto Alegre 9
Abuja 8
Ardabil 8
Frankfurt am Main 8
Melbourne 8
Mexico City 8
New Delhi 8
Tashkent 8
Turku 8
Dhaka 7
Haiphong 7
Totale 9.277
Nome #
Use of brain MRI in manganese exposure 209
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 208
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 203
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 192
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 180
Antiretroviral drugs and liver injury. 174
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 173
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 170
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 169
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 169
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 168
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 159
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 157
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 155
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 155
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 154
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 154
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 152
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 150
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 149
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 145
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 144
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 144
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 144
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 142
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 141
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 136
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 134
Care of patients with hepatitis C and HIV co-infection. 133
Polymorphic immune restoration syndrome after effective HAART 133
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 131
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 131
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 130
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 130
Mortality for liver disease in patients with HIV infection: a cohort study 130
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 128
Natural history of chronic hepatitis B in co-infected patients. 127
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 126
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 126
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 126
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 125
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 123
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 123
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 123
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 122
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 122
HIV/HCV co-infection: natural history. 121
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 121
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 121
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 120
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 120
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 120
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 120
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 119
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 118
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 118
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 118
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 117
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 116
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 116
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 115
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 114
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 114
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 114
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 113
HCV chronic hepatitis in patients with HIV: clinical management issues 112
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 112
Management of hepatitis C in human immunodeficiency virus-infected patients. 112
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 112
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 111
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 111
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 111
The burden of HIV and hepatitis C virus coinfection. 111
Impact of hepatitis C virus infection on lifestyle. 110
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 110
The use of molecular assays in the management of viral hepatitis. 110
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 110
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 110
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 110
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 110
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 108
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 108
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 107
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 106
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 105
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 105
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 98
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 97
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 96
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 96
HCV infection: pathogenesis, clinical manifestations and therapy. 94
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome 94
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 94
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 93
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 92
Pathogenesis of liver damage in HCV-HIV patients. 86
Risk of developing specific AIDS-defining illnesses in patients coinfected withHIV and hepatitis C virus with or without liver cirrhosis 86
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 84
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 80
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. 80
Totale 12.625
Categoria #
all - tutte 59.795
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.795


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202138 0 0 0 0 0 0 0 0 0 0 0 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/20251.702 8 4 7 237 213 158 156 39 150 148 372 210
2025/20263.245 352 484 166 395 382 237 532 113 152 292 113 27
Totale 13.519